Your browser doesn't support javascript.
loading
Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.
Gonzales, Mitzi M; Wang, Chen-Pin; Short, Meghan I; Parent, Danielle M; Kautz, Tiffany; MacCarthy, Daniel; Satizabal, Claudia L; González, David Andrés; Royall, Donald R; Zare, Habil; O'Bryant, Sid; Maestre, Gladys E; Tracy, Russell P; Seshadri, Sudha.
Afiliação
  • Gonzales MM; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health Science Center San Antonio Texas USA.
  • Wang CP; Department of Neurology University of Texas Health Science Center San Antonio Texas USA.
  • Short MI; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health Science Center San Antonio Texas USA.
  • Parent DM; Department of Population Health Sciences University of Texas Health Science Center San Antonio Texas USA.
  • Kautz T; Education & Clinical Center South Texas Veterans Health Care System, Geriatric Research San Antonio Texas USA.
  • MacCarthy D; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health Science Center San Antonio Texas USA.
  • Satizabal CL; Broad Institute, Massachusetts Institute of Technology Massachusetts Cambridge USA.
  • González DA; Departments of Pathology & Laboratory Medicine, and Biochemistry Larner College of Medicine, University of Vermont Vermont Burlington USA.
  • Royall DR; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health Science Center San Antonio Texas USA.
  • Zare H; Department of Population Health Sciences University of Texas Health Science Center San Antonio Texas USA.
  • O'Bryant S; Education & Clinical Center South Texas Veterans Health Care System, Geriatric Research San Antonio Texas USA.
  • Maestre GE; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health Science Center San Antonio Texas USA.
  • Tracy RP; Department of Population Health Sciences University of Texas Health Science Center San Antonio Texas USA.
  • Seshadri S; Department of Neurology Boston University School of Medicine Massachusetts Boston USA.
Alzheimers Dement (Amst) ; 14(1): e12298, 2022.
Article em En | MEDLINE | ID: mdl-35356487
ABSTRACT

Introduction:

The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults.

Methods:

Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40).

Results:

Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio 1.611 (95% confidence interval 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit.

Discussion:

Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article